Global Recombinant Human EGF Market Growth (Status and Outlook) 2023-2029

Global Recombinant Human EGF Market Growth (Status and Outlook) 2023-2029

Human EGF is a 6-kDa protein with 53 amino acid residues and three intramolecular disulfide bonds. EGF binds to the epidermal growth factor receptor. Initially, human EGF was known as urogastrone.

This report studies the Recombinant Human EGF (Epidermal Growth Factor) obtained by recombinant protein.

LPI (LP Information)' newest research report, the “Recombinant Human EGF Industry Forecast” looks at past sales and reviews total world Recombinant Human EGF sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Human EGF sales for 2023 through 2029. With Recombinant Human EGF sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human EGF industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human EGF landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human EGF portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Human EGF market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human EGF and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human EGF.

The global Recombinant Human EGF market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface.

This stimulates ligand-induced dimerization, activating the intrinsic protein-tyrosine kinase activity of the receptor.

The tyrosine kinase activity, in turn, initiates a signal transduction cascade that results in a variety of biochemical changes within the cell – a rise in intracellular calcium levels, increased glycolysis and protein synthesis, and increases in the expression of certain genes including the gene for EGFR – that ultimately lead to DNA synthesis and cell proliferation.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human EGF market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
≥98% SDS-PAGE
95%-98% SDS-PAGE
<95% SDS-PAGE

Segmentation by application
Scientific Research
Medical Drug
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
FUJIFILM Irvine Scientific
PeproTech, Inc
R&D Systems (Bio-Techne)
Miltenyi Biotec
Thermo Fisher Scientific
Abcam PLC
BioLegend Way
STEMCELL Technologies
Eurofins DiscoverX
RayBiotech, Inc
Prospec-Tany
Tonbo Biosciences
EnQuire Bio
ScienCell Research Laboratories
BioVision, Inc
Abm Inc
Cell Guidance Systems
Creative BioMart
Sino Biological
Cell Sciences
Axol Bioscience

Please note: The report will take approximately 2 business days to prepare and deliver.